New method for determining prognosis of patients with psoriasis (E-PAP)

Area of Science:

• Dermatology
• Clinical Research
• Medical Informatics

Background:

• Psoriasis severity is typically assessed using the Psoriasis Area and Severity Index (PASI).
• Accurate prognosis assessment is crucial for effective psoriasis management and treatment planning.
• Existing methods may not fully capture the dynamic nature of clinical symptoms over time.

Purpose of the Study:

• To introduce and validate a novel method, the Evaluation for Prognosis with Averaged PASI (E-PAP), for assessing psoriasis prognosis.
• To evaluate the clinical utility of E-PAP in tracking symptom changes, treatment efficacy, patient satisfaction, and treatment adjustments.
• To compare the prognostic capabilities of E-PAP in patients receiving uninterrupted monotherapy versus intermittent therapy with cyclosporin A.

Main Methods:

• Developed the E-PAP method by incorporating time (days) into the standard PASI calculation.
• Assessed 14 psoriasis cases, evaluating clinical symptoms, treatment effects, patient satisfaction, and need for further interventions.
• Compared E-PAP values between groups receiving uninterrupted monotherapy and intermittent therapy with cyclosporin A.

Main Results:

• The E-PAP method was used to evaluate clinical symptoms, treatment effects, patient satisfaction, and treatment needs.
• No significant differences were observed in cyclosporin A dosages or adverse reactions between monotherapy and intermittent therapy groups.
• A significant difference in E-PAP values was found between the uninterrupted monotherapy and intermittent therapy groups.

Conclusions:

• The E-PAP method provides a new approach to evaluating psoriasis clinical symptoms over time.
• E-PAP demonstrates potential utility in determining the prognosis of psoriasis patients.
• This method may aid clinicians in optimizing treatment strategies and predicting patient outcomes.